Recent Updates
Recently added Catalysts

Opus Genetics, Inc.

IRDFDA catalysts, PDUFA dates & pipeline intelligence
$4.05
▲ +0.01 · +0.25%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full IRD financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.7052W HIGH $7.07
Volume
730.83 K
Value Traded
2.93 M
Short % Float
13.86%
Days to Cover
8.4
-6.03%Week
+6.02%1 Month
-0.49%3 Month
-8.78%6 Month
-7.19%5 Year
-100%All Time

Cash Data

Unlock IRD cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
391.45 M
EPS (TTM)
-1.41
P/E Ratio
-
Ent. Value
338.13 M
Total Shares
96.65 M
Float Shares
78.40 M
Insiders
18.89%
Institutions
60.27%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 1/2 topline data readout
OPGx-BEST1
BEST1-related retinal disease
Phase 1Gene TherapiesOphthalmology
Unlock every IRD catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

IRD Catalyst Timeline

Dated clinical, regulatory and corporate events for Opus Genetics, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Opus Genetics, Inc.

368Total events
26Upcoming
93Tier-1 (high impact)
2020 to 2029Coverage

Upcoming catalysts 2

T2First Patient Dosed
Subscribe to view catalyst details
OPGx-LCA5
T2Trial Initiation
Subscribe to view catalyst details
OPGx-LCA5

Event history 50

●Quarterly UpdateCorporate
Reported financial results for third quarter ended September 30, 2026
▲Enrollment CompleteOPGx-BEST1Trial
Completion of dosing in higher-dose Cohort 2 of BIRD-1 (11 participants enrolled vs target of 5)
BEST1-related retinal diseases (BVMD and ARB)source ↗
▲Enrollment CompleteOPGx-BEST1Trial
Completed enrollment and dosing of 11 participants in high-dose Cohort 2 of BIRD-1
BEST1-related retinal diseasesource ↗
▲Enrollment CompleteOPGx-LCA5Trial
Registrational Phase 3 trial fully enrolled with 8 participants
LCA5-related inherited retinal diseasesource ↗
▲IND ClearanceOPGx-RDH12IND
FDA clearance of IND for OPGx-RDH12
RDH12-associated Leber congenital amaurosis (RDH12-LCA)source ↗
▲Milestone PaymentCorporate
Regulatory milestone payment to Opus Genetics triggered by FDA approval of RYZUMVI presbyopia sNDA
presbyopiasource ↗
▲Supplemental ApprovalFDA Decision
FDA approval of sNDA for RYZUMVI (phentolamine ophthalmic solution 0.75%) for presbyopia
presbyopiasource ↗
●Management ChangeCorporate
Jamie Lynne Hart, M.S., M.P.H. appointed Executive Director, Executive Operations
▲IND ClearanceOPGx-RDH12IND
FDA cleared IND for OPGx-RDH12 gene therapy in RDH12-LCA
RDH12-associated Leber congenital amaurosis (RDH12-LCA)source ↗
▲Supplemental ApprovalFDA Decision
FDA approves sNDA for phentolamine ophthalmic solution 0.75% (RYZUMVI) for presbyopia in adults
presbyopiasource ↗
Unlock the full IRD catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How IRD actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-21OPGx-RDH12 (gene therapy for RDH12 gene mutations) IND Submission IND
Unlock 10 more IRD historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
4
Drugs Scored
rNPV / MCap
Top Drug
Top 24%
Micro Cap
(rank 175 of 725)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-Q), to Sep 2026)
Showing 15 of 15 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Phentolamine Ophthalmic Solution Small MoleculesNCT07140783Vision Loss NightPhase 3 RECRUITING 580Aug 1, 2027
OPGx-LCA5 Gene TherapiesNCT05616793LCA5Phase 1/2 RECRUITING 22Jun 15, 2028
OPGx-RDH12 Gene TherapiesNCT07681778Leber Congenital AmaurosisPhase 1/2 RECRUITING 10Jul 1, 2034
OPGx-BEST1 Gene TherapiesNCT07185256ARBPhase 1/2 RECRUITING 10Aug 1, 2030
Phentolamine Ophthalmic Solution Small MoleculesMarketedNCT06542497PresbyopiaApproved COMPLETED 569Jan 22, 2026
Phentolamine Ophthalmic Solution Small MoleculesNot countedNCT03960866Open Angle GlaucomaPhase 2 COMPLETED 39Sep 11, 2019
Phentolamine Ophthalmic Solution Small MoleculesNot countedNCT04004507Decrease in Night VisionPhase 2 COMPLETED 24Feb 1, 2008
Phentolamine Ophthalmic Solution Small MoleculesMarketedNCT04024891MydriasisApproved COMPLETED 32Sep 17, 2019
Phentolamine Ophthalmic Solution Small MoleculesNot countedNCT01703559Night Vision ComplaintsPhase 2 COMPLETED 60Apr 30, 2012
APX3330 Small MoleculesCompletedNCT04692688Diabetic RetinopathyPhase 2 COMPLETED 103Jan 25, 2023
Phentolamine 0.75% Small MoleculesNot countedNCT06349759Mesopic VisionPhase 3 COMPLETED 200Feb 19, 2026
Phentolamine 0.75% Small MoleculesNot countedNCT04638660Dim Light Vision DisturbancesPhase 3 COMPLETED 144May 19, 2022
Phentolamine 0.75% Small MoleculesMarketedNCT05223478MydriasisApproved COMPLETED 576Apr 28, 2022
Phentolamine Opthalmic 0.75% Small MoleculesMarketedNCT05646719PresbyopiaApproved COMPLETED 333Oct 11, 2023
Phentolamine 0.75% Small MoleculesMarketedNCT04675151PresbyopiaApproved COMPLETED 150Jun 30, 2021
Unlock the IRD pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every IRD program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
OPGx-BEST1 BEST1-related retinal diseasesPhase 1/22026-11-05All five participants demonstrated clinically meaningful improvement in at least one functional measure; BCVA improvement in 60% (3/5); LLVA improvement in 40% (2/5); contrast sensitivity improvement in 40% (2/5); 75% (3/4) demonstrated clinically meaningful improvement by microperimetry; 67% of participants with BVMD (2/3) showed reductions in vitelliform material; reductions in intraretinal fluid in both participants with ARB (2/2)Read MoreOpus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal DiseasesRead More
Scroll for more · summaries link to the source press release
Unlock every IRD trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock IRD insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Magrath GeorgeDirector, Officer (Chief Executive Officer)Sell -28,258 2,010,636 held$3.90 11/03/2026
Unlock the full IRD insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
PERCEPTIVE ADVISORS LLC 0.8 % 43.56 M 9.00 M
Unlock every fund holding IRD
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in IRD
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see IRD ownership
Insider and institutional ownership, quarter by quarter.

IRD Short Interest

Shares sold short, counted twice a month.

13.86%
Short % of Float
of tradable shares sold short
10.9M
Shares Sold Short
-18.5% vs prior count
8.4 High
Days to Cover
trading days of normal volume to buy every short share back
1.3M
Avg Daily Volume
the average used for days to cover
Unlock IRD short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock IRD option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live IRD option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock IRD options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How IRD ranks across every disease it competes in

Competitive Position is a premium feature
See how IRD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

IRD News

IRD
Nov 10, 2026
IRDGeneral

Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update

Opus Genetics reported positive advancements in its gene therapy programs, including successful dosing completion for OPGx-BEST1 and full enrollment for OPGx-LCA5's Phase 3 trial. The company received FDA clearance for OPGx-RDH12, with dosing expected to begin in Q4 2026. Despite a net loss of $46.5 million for Q3 2026, the company anticipates a cash runway into 2029.

Read more →
IRD
Nov 5, 2026
IRDPhases
▼ -6.2%on this newsshared move

Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases

Opus Genetics completed dosing in Cohort 2 of its Phase 1/2 trial for OPGx-BEST1, targeting BEST1-related retinal diseases. The trial exceeded its participant target, with 11 enrolled. Topline data is expected in Q1 2027, and a pivotal Phase 3 trial may begin in the latter half of 2027. Initial results from Cohort 1 showed promising improvements in visual function.

Read more →
IRD
Nov 3, 2026
IRDConferences/Events
▲ +6.2%on this newsshared move

Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference

Opus Genetics will participate in a Fireside Chat at the Guggenheim Annual Healthcare Innovation Conference on November 10, 2026. The company focuses on gene therapies for inherited retinal diseases, with a pipeline that includes seven AAV-based programs. Notable candidates include OPGx-LCA5 and OPGx-BEST1, aimed at addressing genetic causes of retinal disorders.

Read more →
IRD
Nov 2, 2026
IRDGeneral
▲ +6.2%on this newsshared move

Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Opus Genetics announced the approval of equity awards for ten non-executive employees. The awards, totaling 1,100,000 shares, are part of the company's 2021 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4). These options will vest over four years, enhancing employee retention and engagement.

Read more →
IRD
Oct 29, 2026
IRDGeneral

Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations

Opus Genetics appointed Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations. These appointments aim to enhance the company's scientific and operational capabilities as it advances its gene therapy pipeline for inherited retinal diseases. Both leaders bring significant experience in biotechnology and ophthalmology.

Read more →
IRD
Oct 21, 2026
IRDFDA Updates

Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness

Opus Genetics announced FDA clearance of its IND application for OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis. This clearance allows the company to initiate a Phase 1/2 clinical trial. The collaboration with the Global RDH12 Alliance aims to accelerate development for this rare condition affecting childhood vision.

Read more →
IRD
Oct 16, 2026
IRDFDA Updates

Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics has received FDA approval for phentolamine ophthalmic solution 0.75% to treat presbyopia, a common age-related vision condition. This approval follows successful Phase 3 trials, which met all efficacy endpoints. The treatment offers a non-invasive option for adults, enhancing near vision without affecting distance vision. The approval also activates a milestone payment for Opus Genetics.

Read more →
IRD
Oct 15, 2026
IRDPhases
▼ -5.2%on this newsshared move

Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026

Opus Genetics presented promising clinical data for its gene therapy programs OPGx-BEST1 and OPGx-LCA5 at Retina in Rio 2026. The OPGx-BEST1 trial showed improved retinal sensitivity in 75% of participants, while OPGx-LCA5 demonstrated sustained visual acuity improvements over 24 months. The company aims to advance both programs, with Phase 3 dosing for OPGx-LCA5 expected in late 2026.

Read more →
IRD
Oct 13, 2026
IRDConferences/Events
▼ -8.6%on this newsshared move

Opus Genetics to Present at the Chardan Annual Healthcare Conference

Opus Genetics, a clinical-stage biopharmaceutical company, will present at the Chardan Annual Healthcare Conference on October 20, 2026. The company focuses on developing gene therapies aimed at restoring vision for patients with inherited retinal diseases. Their pipeline includes several AAV-based programs targeting various genetic mutations.

Read more →
IRD
Sep 9, 2026
IRDPhases
▲ +32%on this news

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

Opus Genetics announced positive results from the low-dose Cohort 1 of its Phase 1/2 clinical trial for OPGx-BEST1, showing significant improvements in visual function among participants. The FDA has aligned with the company on potential pivotal endpoints, paving the way for a Phase 3 trial expected to start in 2027. The trial demonstrated a favorable safety profile with no serious adverse events reported.

Read more →
IRD
Sep 2, 2026
IRDConferences/Events
▲ +16.2%on this news

Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

Opus Genetics is set to present topline data from its Phase 1/2 OPGx-BEST1 gene therapy program during an investor conference call on September 9, 2026. The company will also showcase the full clinical dataset at several upcoming ophthalmology conferences. This initiative aims to address inherited retinal diseases, particularly BEST1-related conditions.

Read more →
IRD
Aug 19, 2026
IRDGeneral

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics, a clinical-stage biopharmaceutical company, has approved equity awards for three new non-executive employees as part of its 2021 Inducement Plan. The awards, totaling 310,000 stock options, are designed to incentivize employment and comply with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, promoting long-term commitment.

Read more →
IRD
Aug 6, 2026
IRDGeneral

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Opus Genetics reported its financial results for Q2 2026, highlighting significant advancements in its gene therapy programs for inherited retinal diseases. The company completed enrollment in the LCA5 registrational trial and plans to initiate dosing in Q4 2026. With a cash runway extending into 2029, Opus is positioned to pursue multiple clinical studies and potential product approvals.

Read more →
IRD
Aug 3, 2026
IRDPhases

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Opus Genetics has completed patient enrollment in its Phase 3 trial for OPGx-LCA5, a gene therapy targeting LCA5-associated inherited retinal disease. This milestone follows FDA alignment on the trial's design under the Rare Disease Evidence Principles program. The company anticipates topline efficacy data by the end of 2027 and aims to submit a Biologics License Application based on these results.

Read more →
IRD
Jul 9, 2026
IRDPhases

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

Opus Genetics has provided an update on its OPGx-BEST1 Phase 1/2 clinical trial targeting BEST-1 associated inherited retinal diseases. The company expects to release three-month topline data from Cohort 1 in September 2026 and present findings at the EURETINA Congress in October. The trial aims to evaluate the safety and efficacy of OPGx-BEST1, with potential for further development based on results.

Read more →
IRD
Jul 6, 2026
IRDPhases

Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease

Opus Genetics has received FDA alignment on the design of its Phase 3 trial for OPGx-LCA5, a treatment for LCA5-associated inherited retinal disease. The trial will involve eight participants and aims to demonstrate significant improvement in retinal sensitivity. The company anticipates initiating dosing in Q4 2026 and may submit a BLA based on early efficacy data.

Read more →
IRD
Jun 26, 2026
IRDGeneral
▲ +7.5%on this news

Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes

Opus Genetics, a clinical-stage biopharmaceutical company, announced its inclusion in the Russell 3000®, Russell 2000®, and Russell Microcap® indexes, effective June 29, 2026. This membership reflects the company's advancements in developing gene therapies for inherited retinal diseases. The CEO expressed optimism about the increased visibility and validation this brings to their strategic initiatives.

Read more →
IRD
Jun 16, 2026
IRDGeneral

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Opus Genetics is advancing five gene therapy programs aimed at treating inherited retinal diseases (IRDs), with four clinical data readouts expected by 2027. The company plans to initiate clinical testing for three new programs within the next 18 months, leveraging a strong cash runway that extends into 2029. The R&D Science Forum highlighted the potential for accelerated approvals and significant commercial opportunities across its pipeline.

Read more →
IRD
Jun 16, 2026
IRDConferences/Events

Opus Genetics R&D Science Forum

The Opus Genetics R&D Science Forum was held on June 16, 2026, highlighting the company's forward-looking statements regarding its clinical trials and product pipeline. The presentation discussed risks associated with gene therapy product candidates and emphasized the uncertainties surrounding future operating performance. A panel of experts provided insights into various topics, including clinical strategy and disease prevalence, while addressing potential challenges in patient recruitment and regulatory approvals. The forum aimed to communicate Opus Genetics' vision amidst complex industry dynamics.

Read more →
IRD
Jun 2, 2026
IRDConferences/Events

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

Opus Genetics will host a virtual R&D Science Forum on June 16, 2026, featuring experts discussing their gene therapy pipeline for inherited retinal diseases. The forum will cover three gene therapy programs targeting specific genetic mutations and present data from ongoing clinical programs. The event aims to highlight the company's progress and strategic plans in addressing vision loss.

Read more →

About Opus Genetics, Inc.

Durham, NC 28 employees opusgtx.com
Headquarters8 DAVIS DRIVE, DURHAM, NC, 27713
BIOPHARMAWATCH ELITE
Trade the next IRD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime